News

Article

Astellas Sells Research Facilities to Gilead’s Kite Pharma

As Astellas Pharma winds down its Agensys research operations, the company sells the Santa Monica, CA, facility to Gilead.

Astellas Pharma announced on April 18, 2018 that it has sold certain Agensys research facilities in Santa Monica, CA, to Gilead’s Kite Pharma. 

The transaction was completed on April 12, 2018. Additional financial information or further deal terms were disclosed.

The sale of the facility comes as Astellas winds down its research operations at Agensys, which it announced in July 2017. 

Additional wind-down activities were completed in the first quarter of 2018 following the company's decision to refine its oncology strategy by expanding its investment in the research of new technologies and modalities. More specifically, the company is reducing its focus on antibody-drug conjugate (ADC) research, which was the core focus of work conducted at Agensys. 

The company also reports that it will continue certain clinical trials and collaborations on some ADC programs that have been in progress at Agensys, including its collaboration with Seattle Genetics.

Source: Astellas

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Related Content